COVID-19 vaccination, dengue hepatitis, and recurrent unilateral anterior uveitis.
Indian J Ophthalmol
; 71(5): 2269-2272, 2023 05.
Article
in English
| MEDLINE | ID: covidwho-2326049
ABSTRACT
A 36-year-old Asian Indian male presented with redness and pain in his right eye of 1 week duration. He was diagnosed to have right acute anterior uveitis and had a history of being admitted at a local hospital for dengue hepatitis a month earlier. He had been on adalimumab 40 mg three weekly once and oral methotrexate 20 mg/week for human leucocyte antigen (HLA) B27 spondyloarthropathy and recurrent anterior uveitis. Our patient had re-activation of his anterior chamber inflammation on three distinct occasions first, 3 weeks following recovery from coronavirus disease 2019 (COVID-19), the second after the second dose of COVID-19 vaccination, and the third after recovery from dengue fever-associated hepatitis. We propose molecular mimicry and bystander activation as the postulated mechanisms for the re-activation of his anterior uveitis. In conclusion, patients with auto-immune diseases can have recurrent ocular inflammation following COVID-19 or its vaccination or dengue fever as seen in our patient. The anterior uveitis is usually mild and responds to topical steroids. Additional immuno-suppression may not be needed. Mild ocular inflammation following vaccination should not deter individuals from getting COVID-19 vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Uveitis
/
Uveitis, Anterior
/
Dengue
/
COVID-19
/
Hepatitis
/
Hepatitis A
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Indian J Ophthalmol
Year:
2023
Document Type:
Article
Affiliation country:
Ijo.IJO_2064_22
Similar
MEDLINE
...
LILACS
LIS